- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01904877
Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men -Test, Link and Care (TLC) (MP3)
Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men -Test, Link and Care (TLC) Version 1.0 Dated 10/15/12
- The number of MSM who are tested for HIV in the 4 study clinics over 12 months will increase compared with historical data from the same 4 clinics over the past 12 months prior to the intervention.
- Persons diagnosed with HIV over the duration of 12 months will have higher CD4 counts at diagnosis than persons diagnosed with HIV over the past 12 months prior to the intervention
Study Overview
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:• Men who had sex with another man in the last 12 months based on self-reporting (sex can be defined as oral, anal, or mutual masturbation)(including transgendered women)(including transgendered women);
- Aged 18 years or older;
- Living and/or working in the defined districts of municipal Beijing;
- Able and willing to adequately grant informed consent. For the purposes of this activity participants must consent to questionnaire surveys, receipt of phone messages, and serological testing;
- Having not previously participated in HIV testing in this study.
Besides these criteria, additional criteria for the HIV Linkage and Care pilot Research Clinical Trial are:
- Men who are being identified as HIV positive during the testing campaign in Phase I of the study;
- No plan to leave Beijing in the next 12 months.
- Willing to comply with study procedures.
- Having a cell phone and willing to receive study related SMS texts
Exclusion Criteria:
Having previously been found to be HIV positive based on self-reporting during eligibility screening;
- Serious psychological disturbance or cognitive impairment interfering with the participant's ability to comply with the study visit schedule and procedures, as judged by the local study clinician;
- Any other medical or psychiatric condition that, in the opinion of the investigator, would make participation in the study unsafe, or otherwise interfere substantially with the study objectives or interpretation.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HIV testing
Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
|
SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
Other Names:
|
Phase II: 367 HIV positive MSM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
(Primary) phase I: The number of MSM who are tested for HIV in 4 study clinics over 12 months will increase significantly compared with historical data from the same 4 clinics over the past 12 months prior to the intervention
Time Frame: 12 months
|
The effect of intervention on the monthly number of MSM who receive HIV testing prior to and after intervention at 4 clinics will be evaluated using a generalized estimating equation (GEE) model with robust variance estimates to account for correlation in outcomes within a clinic
|
12 months
|
Phase II: A higher proportion of participants in the intervention arm will obtain their CD4 results and ART eligibility assessment in a CDC clinic within 1 month of being diagnosed with HIV than in the comparison arm experienced a local standard of care.
Time Frame: 1 month
|
The proportion of participants randomized to the intervention arm who obtain their CD4 count results within 1 month of randomization will be compared to the same proportion in the comparison arm using logistic regression.
The primary analysis will adjust for the following baseline covariates: clinic, CD4 count, ART eligibility, self-reported drug abuse, self-reported alcohol abuse, and age.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Persons diagnosed with HIV over the duration of 12 months will have higher CD4 counts at diagnosis than persons diagnosed with HIV over the past 12 months prior to the intervention.
Time Frame: 12 month
|
We will compare the distribution of CD4 counts immediately after HIV diagnosis for all MSM diagnosed with HIV at one of the 4 clinics for the 12 months during the intervention period versus the 12 months prior to the intervention using a Wilcoxon rank sum test
|
12 month
|
Phase II:A higher proportion of ART eligible participants in the intervention arm will receive their first HIV medical care within 3 months of diagnosis than in the comparison arm.
Time Frame: 12 months
|
A logistic regression analysis will be performed to assess the association between intervention and timely receipt of first HIV medical care among those who are ART eligible (CD4<350).
The analysis will adjust for the following baseline covariates: clinic, CD4 count, self-reported drug abuse, self-reported alcohol abuse, and age.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase II: A higher proportion of participants in the intervention arm will obtain their CD4 results and ART eligibility assessment in a CDC clinic within 1 month of being diagnosed with HIV than in the comparison arm experienced a local standard of care.
Time Frame: 36 months
|
To evaluate the efficacy of interactive SMS-II with peer education/counseling intervention for reducing risky sexual behaviors among HIV-infected Chinese MSM over the first year of HIV-care
|
36 months
|
Collaborators and Investigators
Investigators
- Study Chair: Sten H Vermund, MD,PhD, Vanderbilt Institue for Global Health
- Study Director: Han-Zhu Qian, MD,PhD, Vanderbilt Institue for Global Health
- Study Director: Yiming Shao, MD,PhD, Division of Immunology and Microbiology NCAIDS, China CDC
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 11914
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on Enhancing HIV testing
-
Harvard School of Public Health (HSPH)University of Heidelberg Medical Center; University of Witwatersrand, South...UnknownHIV Infections | Knowledge, Attitudes, PracticeSouth Africa
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV InfectionsSouth Africa
-
Makerere UniversityUniversity of California, San FranciscoCompleted
-
University of OxfordNational Institute of Allergy and Infectious Diseases (NIAID); University of...Completed
-
Hopital LariboisièreCompleted
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Emory UniversityNational Institute of Mental Health (NIMH)Completed
-
National Development and Research Institutes, Inc.National Institute on Drug Abuse (NIDA)Completed
-
Evandro Chagas National Institute of Infectious...Valdiléa Veloso dos Santos, Ph.D.; Beatriz Grinzstejn, MD, PhD; Brenda Hoagland... and other collaboratorsCompletedHIV Infections | Risk Behavior | HIV Seropositivity | Risk Reduction | STD | HIV Infection Primary | Risky Health BehaviorBrazil
-
University of Witwatersrand, South AfricaCompleted